Department of Biochemistry, Faculty of Medicine, Mersin University, Mersin, 33079, Turkey.
Mol Biol Rep. 2013 Mar;40(3):2091-6. doi: 10.1007/s11033-012-2267-7. Epub 2012 Dec 1.
Gastric cancer is the fourth most prevalent malignancy worldwide and remains the second most common cause of cancer-related death globally. Understanding the molecular structure of gastric carcinogenesis might identify new diagnostic and therapeutic strategies for this disease. Thus, early detection of gastric cancer is a key measure to reduce the mortality and improve the prognosis of gastric cancer. There have recently been several reports that microRNAs (miRNAs) circulate in highly stable, cell-free forms in blood. Because serum and plasma miRNAs are relatively easy to access, circulating miRNAs also have great potential to serve as non-invasive biomarkers. Although a number of miRNAs associated with gastric cancer have been identified, the underlying mechanism of these miRNAs in tumorigenesis and tumor progression remains to be investigated. The purpose of this study is to identify the potential of serum miRNAs as biomarkers for early detection of gastric cancer patients. RNA was isolated using the High Pure miRNA Isolation Kit (Roche) following the manufacturer's protocol. cDNA and preamplification protocols were obtained from the isolated plasma miRNAs. The BioMark™ 96.96 Dynamic Array (Fluidigm Corporation) for real-time qPCR was used to simultaneously quantite the expression of 740 miRNAs. All statistical analyses were performed using the Biogazelle's qbase PLUS 2.0 software. In this study, among 740 miRNAs that we analyzed only miR-195-5p was significantly (p < 0.05, fold changes = 13, 3) down-regulated in gastric cancer patients compared with control. We demonstrated that miR-195-5p is a novel tumor suppressor miRNA and may contribute to gastric carcinogenesis. The miRNA expression profile described in this study should contribute to future studies on the role of miRNAs in gastric cancer.
胃癌是全球第四大常见恶性肿瘤，仍是全球癌症相关死亡的第二大主要原因。了解胃癌发生的分子结构可能为这种疾病确定新的诊断和治疗策略。因此，早期发现胃癌是降低胃癌死亡率和改善预后的关键措施。最近有几项报道称，microRNAs（miRNAs）以高度稳定的无细胞形式循环存在于血液中。由于血清和血浆中的 miRNAs 相对容易获得，因此循环 miRNAs 也具有作为非侵入性生物标志物的巨大潜力。虽然已经确定了许多与胃癌相关的 miRNAs，但这些 miRNAs 在肿瘤发生和肿瘤进展中的潜在机制仍有待研究。本研究旨在确定血清 miRNAs 作为胃癌患者早期检测的潜在生物标志物。按照制造商的方案，使用 High Pure miRNA Isolation Kit（Roche）分离 RNA。从分离的血浆 miRNAs 中获得 cDNA 和预扩增方案。使用 BioMark™ 96.96 Dynamic Array（Fluidigm Corporation）进行实时 qPCR，以同时定量 740 种 miRNA 的表达。所有统计分析均使用 Biogazelle 的 qbase PLUS 2.0 软件进行。在这项研究中，在我们分析的 740 种 miRNA 中，miR-195-5p 在胃癌患者中明显（p<0.05，倍数变化=13，3）下调。我们证明 miR-195-5p 是一种新的肿瘤抑制 miRNA，可能有助于胃癌的发生。本研究中描述的 miRNA 表达谱应有助于未来对 miRNA 在胃癌中的作用的研究。
